(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.
The Global Metabolism Drugs Market, valued at approximately USD 16.10 billion in 2022, is projected to grow at a robust CAGR of more than 6.50% during the forecast period from 2023 to 2030. Metabolism ...
report_id=bw7622 North America: Dominates the market with the largest share due to high usage of nutritional supplements, a higher prevalence of chronic diseases, and increased incidence of obesity.
The disease burden has shifted in recent years as the prevalence of NCDs has risen, linked largely to poor nutrition, and overweight and obesity levels. Another major factor is the prevalence ... you ...